Several new topical agents have been introduced recently and it can be expected that the treatment of glaucoma will change, depending on how effectively these agents control intraocular pressure (IOP).
IOP is considered the major risk factor in the development of glaucomatous damage.
In order to estimate the impact of these new agents on the cost of treating glaucoma, a simulation model was created to estimate the cost of treating patients with a recent diagnosis of primary open-angle glaucoma or ocular hypertension in different countries.
The Markov model is based on retrospective chart reviews in different countries and calculates only cost, not outcome.
Results are presented for France and the United Kingdom, where current treatment appeared to be comparable.
Average one-year costs per patient with current treatment were FF2,389 (US $389) and £380 (US $627), respectively.
Costs with the new treatments were lower than with current therapy.
Mots-clés Pascal : France, Europe, Royaume Uni, Glaucome, Traitement, Analyse coût, Modélisation, Aide décision, Analyse décision, Voie locale, Chimiothérapie, Modèle Markov, Analyse avantage coût, Economie santé, Coût moyen, Etude longitudinale, Oeil pathologie
Mots-clés Pascal anglais : France, Europe, United Kingdom, Glaucoma (eye), Treatment, Cost analysis, Modeling, Decision aid, Decision analysis, Local administration, Chemotherapy, Markov model, Cost benefit analysis, Health economy, Average cost, Follow up study, Eye disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0343967
Code Inist : 002B02M. Création : 14/12/1999.